Pricing Log in Create free account

Akari Therapeutics PLC (AKTX) vs TScan Therapeutics, Inc. (TCRX)

Akari Therapeutics PLC and TScan Therapeutics, Inc. are both Biotechnology companies. Akari Therapeutics PLC and TScan Therapeutics, Inc. are of similar size ($16.2M and $15.5M). Akari Therapeutics PLC has the higher net margin (0.00% vs −1,655.4%) and the higher return on invested capital (−167.9% vs −4,588.2%). Across the 14 metrics below, Akari Therapeutics PLC leads on 9 and TScan Therapeutics, Inc. on 5.

Valuation

Metric AKTX TCRX Biotechnology median
P/E n/m n/m 8.50
P/S n/m 4.20 9.71
P/B 0.79 0.43 2.13
Price to free cash flow n/m n/m 20.82
EV/EBITDA n/m 0.32 0.64
EV/Sales n/m (5.27) 9.21
Earnings yield (316.31%) (395.65%) (33.15%)
Free cash flow yield (73.67%) (396.18%) (25.50%)

Profitability

Metric AKTX TCRX Biotechnology median
Gross margin 0.00% 100.00% 65.16%
Operating margin 0.00% (1,695.15%) 0.00%
Net margin 0.00% (1,655.35%) 0.00%
Free cash flow margin 0.00% (1,665.18%) 0.00%
Return on equity (140.09%) (95.80%) (56.36%)
Return on assets (69.16%) (50.09%) (48.04%)
Return on invested capital (167.93%) (4,588.23%) 0.00%

Growth

Metric AKTX TCRX Biotechnology median
Revenue growth (TTM) — 2.15% 6.02%
EPS growth (last fiscal year) 68.99% 12.28% 30.26%
Revenue growth, 5-year CAGR — 56.92% 9.41%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric AKTX TCRX Biotechnology median
Debt to equity 0.04 0.47 0.00
Current ratio 0.60 3.37 4.72
Net debt to EBITDA 0.27 0.90 0.96

Dividend

Metric AKTX TCRX Biotechnology median
Dividend yield — — 0.09%
Payout ratio — — —

Size

Metric AKTX TCRX Biotechnology median
Market cap 15.47m 16.21m 135.18m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack